ClinicalTrials.gg
RecruitingNCT07830758Updated Nov 12, 2026

Resmetirom in Patients With MASH and HFpEF

A Phase 1 interventional study of Resmetirom and Placebo in MASH - Metabolic Dysfunction-Associated Steatohepatitis and Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Madrigal Pharmaceuticals, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 12, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
57th of 162
90 · median 45
Started
2026
with 13 others
Phase 1
18 of 211
3 open now
Primary completion
2027-11
later than 20 of 46 live
Registered
208th of 211
by date

Among the 211 studies in Fatty Liver with a site in United States, this one is the 57th largest by planned enrollment of the 162 interventional ones that give a count, is one of 14 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 20 of the 46 other live ones, and was the 208th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.

03

Conditions studied

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • Heart Failure With Preserved Ejection Fraction (HFPEF)

Keywords

  • MASH
  • HFPEF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be willing to participate in the study and provide written .
  2. Male and female adults ≥18 years of age.
  3. Suspected or confirmed diagnosis of fibrotic MASH suggested by the historical data and meets at least 1 criteria for fibrotic MASH
  4. Confirmed diagnosis of HFpEF
  5. Structural and/or functional heart disease based on echocardiographic evaluation.
  6. ≥45 mL/min/1.73 m2
  7. Female patients of are eligible if they have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use 1 highly effective method during the study and for at least 30 days after study drug administration. Highly effective birth control methods include hormonal and non-hormonal intrauterine device, combination estrogen-progesterone hormonal contraception (oral, transdermal, or vaginal), tubal ligation, a vasectomized or sterile male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from Screening, throughout the study and for at least 30 days after study drug administration.

Exclusion criteria

Exclusion Criteria:

  1. Patients with cirrhosis and other etiologies of chronic liver disease
  2. PEth value of ≥20 ng/mL measured at Screening OR history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening.
  3. Thyroid disease:

    1. Active hyperthyroidism
    2. Untreated clinical hypothyroidism defined by TSH >7 IU/L with symptoms of hypothyroidism or >10 IU/L without symptoms
  4. History of bariatric surgery or intestinal bypass surgery within the 5 years prior to randomization or planned during the conduct of the study
  5. Weight gain or loss >5% total body weight within 12 weeks prior to randomization
  6. >9.0%
  7. Diagnosis of HCC
  8. MELD score ≥12, as determined at Screening, due to liver disease
  9. Hepatic decompensation or impairment.
  10. Has an active disease, including actively treated lupus, rheumatoid arthritis, inflammatory bowel disease, or autoimmune hepatitis, requiring systemic treatment within the past 12 weeks or a documented history of clinically severe autoimmune disease, including autoimmune liver disease, or a syndrome that requires systemic or agents
  11. Serum >250 U/L
  12. count \<140,000/mm3. Patients with platelets \<140,000 and ≥120,000/mm3 are eligible if FIB-4 score \<3.5.
  13. History of biliary diversion
  14. Uncontrolled hypertension (either treated or untreated) defined as systolic blood pressure >170 mmHg or a diastolic blood pressure >100 mmHg at Screening
  15. Confirmed >450 msec for males and >470 msec for females at the Screening assessment;
  16. Presence of sustained atrial fibrillation at time of Screening or history of paroxysmal atrial fibrillation episodes for the last 3 months prior to Screening
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Resmetirom

    Participants will receive resmetirom orally once daily for 24 weeks. Resmetirom dose will be based on actual body weight: 80 mg once daily for participants weighing \<100 kg and 100 mg once daily for participants weighing ≥100 kg. Dose reduction by 20 mg will be implemented for concomitant use of a moderate CYP2C8 inhibitor, as specified in the protocol

    Drug: Resmetirom

  • Placebo comparator
    Arm 2 - Placebo Comparator

    Participants will receive matching placebo orally once daily for 24 weeks.

    Drug: Placebo

Interventions

  • Resmetirom (80 mg or 100 mg orally once daily based on body weight)

  • DrugPlacebo

    Matching placebo orally once daily

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From first dose through End of Study follow-up (28 days after last dose)

  2. Incidence of treatment-emergent serious adverse events (SAES)

    Time frame: From first dose through End of Study follow-up (28 days after last dose)

  3. Change from baseline in physical examination findings assessed by investigator physical examination

    Physical examination findings will be assessed by the Investigator and include general appearance, skin, head and neck, heart, lungs, abdomen, extremities, and neuromuscular assessments. After Screening and successful Randomization, physical examinations may be targeted to evaluation of new symptoms or signs.

    Time frame: Baseline to Week 24

  4. Change from baseline in body temperature

    Body temperature will be measure in °C, resting heart rate in beats per minute, respiratory rate in breaths per minute, systolic blood pressure in mmHg, and diastolic blood pressure in mmHg

    Time frame: Baseline to Week 24

  5. Change from baseline resting heart rate

    Resting heart rate will be measured in beats per minute (bpm)

    Time frame: Baseline to Week 24

  6. Change from baseline in respiratory rate

    Respiratory rate will be measured in breaths per minute.

    Time frame: Baseline to Week 24

  7. Change from baseline in seated systolic blood pressure

    Resting seated systolic blood pressure will be measured in millimeters of mercury (mmHg)

    Time frame: Baseline to Week 24

  8. Change from baseline in seated diastolic blood pressure

    Resting seated diastolic blood pressure will be measured in millimeters of mercury (mmHg)

    Time frame: Baseline to Week 24

  9. Change from baseline in PR interval on 12-lead ECG in milliseconds (ms)

    Time frame: Baseline to Week 24

  10. Change from baseline in QRS interval on 12-lead ECG in milliseconds (ms)

    Time frame: Baseline to Week 24

  11. Change from baseline in heart rate on 12-lead ECG in beats per minute (bpm)

    Time frame: Baseline to Week 24

  12. Change from baseline in RR interval on 12-lead ECG in milliseconds (ms)

    Time frame: Baseline to Week 24

  13. Change from baseline in QT interval on 12-lead ECG in milliseconds (ms)

    Time frame: Baseline to Week 24

  14. Change from baseline in QT interval corrected using Bazett's formula (QTcB) in milliseconds (ms)

    Time frame: Baseline to Week 24

  15. Change from baseline in QT interval corrected using Fridericia's formula (QTcF) in milliseconds (ms)

    Time frame: Baseline to Week 24

  16. Number of participants with clinically significant abnormalities in hematology laboratory parameters

    Hematology laboratory parameters include hemoglobin, hematocrit, red blood cell count, white blood cell count, platelet count, red blood cell indices, and differential leukocyte counts. The number of participants with clinically significant abnormalities, as determined by the Investigator, will be summarized by treatment group.

    Time frame: Baseline to Week 24

  17. Number of participants with clinically significant abnormalities in blood chemistry laboratory parameters

    Blood chemistry laboratory parameters include measures of hepatic function, renal function, glucose metabolism, pancreatic function, electrolytes, bilirubin, and serum proteins. The number of participants with clinically significant abnormalities, as determined by the Investigator, will be summarized by treatment group.

    Time frame: Baseline to Week 24

  18. Number of participants with clinically significant abnormalities in urinalysis parameters

    Urinalysis parameters include pH, specific gravity, protein, glucose, ketones, bilirubin, blood, nitrite, urobilinogen, and leukocyte esterase. The number of participants with clinically significant abnormalities, as determined by the Investigator, will be summarized by treatment group.

    Time frame: Baseline to Week 24

  19. Percent change from baseline in liver fat content measured by MRI-Proton Density Fat Fraction (MRI-PDFF)

    Time frame: Baseline to Week 24

07

Study locations

5 of 5 sites recruiting
  • Arizona Clinical Trials
    Peoria, Arizona 85382, United States
    Recruiting
  • FOMAT - Clinicas Mi Salud
    Oxnard, California 93030, United States
    Recruiting
  • Covenant Metabolic Specialist
    Fort Myers, Florida 33912, United States
    Recruiting
  • Covenant Metabolic Specialist
    Riverview, Florida 33578, United States
    Recruiting
  • Covenant Metabolic Specialist
    University Park, Florida 34201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 13 months after the start.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 13 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 21, 2026
StartActual
Oct 16, 2026was Sep 2026
Primary completionEst.
Nov 2027
CompletionEst.
Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
5 sites added — first site in United States
Show 5 added (5 United States)
  • Arizona Clinical Trials · Peoria, United States
  • FOMAT - Clinicas Mi Salud · Oxnard, United States
  • Covenant Metabolic Specialist · Fort Myers, United States
  • Covenant Metabolic Specialist · Riverview, United States
  • Covenant Metabolic Specialist · University Park, United States
Oct 16, 2026
Start date
Sep 2026→Oct 16, 2026 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Start date Sep 2026→Oct 16, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    5 sites added — first site in United States
    Show 5 added (5 United States)
    • Arizona Clinical Trials · Peoria, United States
    • FOMAT - Clinicas Mi Salud · Oxnard, United States
    • Covenant Metabolic Specialist · Fort Myers, United States
    • Covenant Metabolic Specialist · Riverview, United States
    • Covenant Metabolic Specialist · University Park, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07830758
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Oct 16, 2026
Primary completion
Nov 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Ashley Magnavita
Contact
amagnavita@madrigalpharma.com
+1 267-806-1293
Uli Frevert, MD
study director · Madrigal Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resmetirom

Start the discussion